GYKI 47261 dihydrochloride structure
|
Common Name | GYKI 47261 dihydrochloride | ||
|---|---|---|---|---|
| CAS Number | 1217049-32-5 | Molecular Weight | 395.713 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H17Cl3N4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of GYKI 47261 dihydrochlorideGYKI-47261 dihydrochloride is a competitive, orally active, and selective AMPA receptor antagonist with an IC50 of 2.5 μM. GYKI-47261 has broad spectrum anticonvulsive activity and neuroprotective effects. GYKI-47261 dihydrochloride is also a potent inducer of CYP2E1[1][2]. |
| Name | 4-(8-Chloro-2-methyl-11H-imidazo[1,2-c][2,3]benzodiazepin-6-yl)aniline dihydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | GYKI-47261 dihydrochloride is a competitive, orally active, and selective AMPA receptor antagonist with an IC50 of 2.5 μM. GYKI-47261 has broad spectrum anticonvulsive activity and neuroprotective effects. GYKI-47261 dihydrochloride is also a potent inducer of CYP2E1[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | GYKI-47261 dihydrochloride (6 mg/kg; i.v.) shows antiischemice effect in a transient focal ischemia model, in rats. GYKI-47261 dihydrochloride (p.o.) potently mitigated the tremor induced by oxotremorine with ED50 of 16.8 mg/kg in male CD1 mice[1]. GYKI-47261 dihydrochloride(20 mg/kg; i.p.) reverses the dopamine depleting effect of MPTP[1]. Animal Model: Male C57 black mice, weighing 23-30 g[1] Dosage: 20 mg/kg Administration: I.p. Result: Reversed the MPTP-induced decrease in striatal concentrations. |
| References |
[1]. Abrahám G, et al. New non competitive AMPA antagonists. Bioorg Med Chem. 2000;8(8):2127-2143. |
| Molecular Formula | C18H17Cl3N4 |
|---|---|
| Molecular Weight | 395.713 |
| Exact Mass | 394.051880 |
| 4-(8-Chloro-2-methyl-11H-imidazo[1,2-c][2,3]benzodiazepin-6-yl)aniline dihydrochloride |
| Benzenamine, 4-(8-chloro-2-methyl-11H-imidazo[1,2-c][2,3]benzodiazepin-6-yl)-, hydrochloride (1:2) |